Directors Dealings
Directors' Dealings
Personal trades by the Management Board
and Supervisory Board
According to article 19 of Market Abuse Regulation, persons with managerial responsibilities, as well as persons closely related to them, are required to report the purchase and sale of Company shares, or other financial instruments relating thereto, to the German Federal Financial Supervisory Authority (BaFin) and to the Company if the total value of such transactions effected within a calendar year is equal to or more than EUR 5,000.
Such transactions are, in accordance with German law, promptly published by Formycon upon such notification.
General information on the following managers transactions announcements
according to article 19 MAR
Description of the financial instrument: Share
Name of issuer: Formycon AG
ISIN of the financial instrument: DE000A1EWVY8
Legal Entity Identifier (LEI) Code: 39120005TZ76GQOY8Z19
| Date | Name | Position | Transaction | Volume | Price in € | Volume in € | Publication |
|---|---|---|---|---|---|---|---|
| 02/21/2025 | Dr. Andreas Seidl | Executive Board Member (CSO) | Purchase | 160 | 30 | 4,800.00 | Download |
| 04/25/2024 | Nicola Mikulcik | Executive Board Member (CBO) | Purchase | 1,200 | 40 | 48,000.00 | Download |
| 04/22/2024 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 2,340 | 39 | 91,260.00 | Download |
| 04/22/2024 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 160 | 38.65 | 6,184.00 | Download |
| 08/30/2022 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Sale | 15,000 | 76.48 | 1,147,200.00 | Download |
| 08/04/2022 | Dr. Stefan Glombitza | Executive Board Member (CEO) | Purchase | 20,000 | 19.46 | 389,200.00 | Download |
| 03/03/2021 | Dr. Stefan Glombitza | Executive Board Member (COO) | Sale | 15,000 | 64.9 | 973,500.00 | Download |
| 03/03/2021 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 7,500 | 64.9 | 486,750.00 | Download |
| 03/03/2021 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 15,000 | 64.9 | 973,500.00 | Download |
| 02/03/2021 | Dr. Stefan Glombitza | Executive Board Member (COO) | Purchase | 15,000 | 19.46 | 291,900.00 | Download |
| 02/03/2021 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 7,500 | 20.7 | 155,250.00 | Download |
| 02/03/2021 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 15,000 | 20.7 | 310,500.00 | Download |
| 11/14/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Sale | 72,000 | 30.9 | 2,224,800.00 | Download |
| 07/23/2019 | Dr. Nicolas Combé | Executive Board Member (CFO) | Others | 25,000 | 5.52 | 138,000.00 | Download |
| 07/23/2019 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Others | 25,000 | 5.52 | 138,000.00 | Download |
| 06/26/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Purchase | 577,397 | 29.9 | 17,264,170.30 | Download |
| 06/05/2019 | Peter Wendeln (Wendeln & Cie. KG) | Member of the Supervisory Board | Others | Not Quantifiable | Not Quantifiable | Not Quantifiable | Download |
| 08/10/2018 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 25,000 | 33.48 | 837,000.00 | Download |
| 08/10/2018 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 25,000 | 33.48 | 837,000.00 | Download |
| 07/21/2018 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 25,000 | 7.59 | 189,750.00 | Download |
| 07/21/2018 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 25,000 | 7.59 | 189,750.00 | Download |
| 09/05/2017 | Dr. Nicolas Combé | Executive Board Member (CFO) | Sale | 15,000 | 31.6 | 474,000.00 | Download |
| 09/05/2017 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Sale | 15,000 | 31.6 | 474,000.00 | Download |
| 07/14/2017 | Dr. Nicolas Combé | Executive Board Member (CFO) | Purchase | 15,000 | 4.33 | 64,950.00 | Download |
| 07/14/2017 | Dr. Carsten Brockmeyer | Executive Board Member (CEO) | Purchase | 15,000 | 4.33 | 64,950.00 | Download |
Voting Rights Notifications
Voting Rights Notifications
Notifications pursuant to Sections 33 et seq. of the
German Securities Trading Act (WpHG)
Under the German Securities Trading Act (WpHG), the shareholders of a German listed company are obliged to inform the Company and the German Federal Financial Supervisory Authority (BaFin) of any changes in voting rights in Formycon AG if they reach, exceed or fall below the statutory thresholds. The voting rights notifications of Formycon AG are shown in the table below.
We kindly request shareholders who are obliged to submit voting right notifications according to §§ 33ff of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG) to send their notification in a readable version (pdf) and the XML file and any annexes for the publication of the notification of voting rights in writing to the e-mail address provided below.
| Date | Notifying party | Type of notification | Publication |
|---|---|---|---|
| 13.11.2024 | Klaus Röhrig | Stimmrechtsmitteilung | Download |
| 13.11.2024 | Florian Schuhbauer | Stimmrechtsmitteilung | Download |
| 11/11/2024 | Thomas Peter Maier | Voting Rights Notification | Download |
| 11/11/2024 | Peter Wendeln | Voting Rights Notification | Download |
| 11/11/2024 | Gedeon Richter | Voting Rights Notification | Download |
| 11/11/2024 | Detlef and Ursula Spruth | Voting Rights Notification | Download |
| 11/11/2024 | Stefan R. | Voting Rights Notification | Download |
IR Contact
Contact
Formycon in Dialogue
A key component of our philosophy is the dialogue with capital market players. The Formycon Investor Relations department will be happy to answer any questions or suggestions you may have.
Sabrina Müller
Director Investor Relations and Corporate Communications
T + 49 89 86 46 67 149 ・ F + 49 89 86 46 67 110
We kindly request shareholders who are obliged to submit voting right notifications according to §§ 33ff of the German Securities Trading Act (Wertpapierhandelsgesetz – WpHG) to send their notification in a readable version (pdf) and the XML file and any annexes for the publication of the notification of voting rights in writing to the e-mail address provided below.
We will keep you up to date!
To receive our publications automatically, simply register for the news distribution list.
Governance (IR)
Corporate Governance
Governance at Formycon
Formycon is committed to the principles of good corporate governance in respect of responsible, transparent and long-term successful management and control of the company. We follow the recommendations and principles of the German Corporate Governance Code.
Documents
With the publication of our annual report 2024, you will also find the remuneration report in this section.
Publications
Financial Reports
Annual, Half-Year and
Quarterly Reports
Key figures and information on the
company's development
9M/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
H1/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Q1/2024
Key Financial Figures
Corporate News
Presentation
Earnings-Call
FY 2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Q3/2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
H1/2023
Key Financial Figures
Corporate News
Presentation
Earnings-Call
Financial Report
Financial reports of recent years
Supervisory Board
Supervisory Board
Strategic advice with a broad perspective
The Supervisory Board of Formycon has many years of entrepreneurial experience.
From left to right: Colin Bond (Deputy Chairman of the Supervisory Board), Nicholas Haggar (Member of the Supervisory Board), Wolfgang Essler (Chairman of the Supervisory Board),
Klaus Röhrig (Member of the Supervisory Board), Dr. Bodo Coldewey (Member of the Supervisory Board).
Wolfgang Essler
Chairman of the Supervisory Board
Deputy Chairman of the Nomination and Remuneration Committee
Wolfgang Essler, who was born on October 20, 1972 in Munich, Germany, studied business administration at the University of Augsburg from 1992 until 1998. He began his professional career in the consulting firms O&R Corporate Finance GmbH (1998-2008) and Duff & Phelps GmbH (2008-2010) with a focus on corporate finance and transactions, followed as a board member at the investment company balandis real estate ag and predecessor companies (2010-2023). Since 2021, he is chief representative (Generalbevollmächtigter) of ATHOS and managing director of Santo Holding (Deutschland) GmbH, i.e. of one of our Major Shareholder.
Alongside his office as a member of the Supervisory Board, Wolfgang Essler is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:
Currently:
- Vanguard AG, deputy chairman of the supervisory board;
- Mega Pharma Holding Uruguay S.A., Montevideo, Uruguay, member of the non-executive board of directors;
- WERK Immobilien GmbH, managing director;
- fidelius Investment GmbH, managing director;
- Santo Holding (Deutschland) GmbH, managing director;
- Terra Quantum AG, St. Gallen, Switzerland, member of the board of directors; and
- balandis real estate GmbH i.L., managing director and liquidator.
Previously: None
Other than listed above, Wolfgang Essler is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.
Colin Bond
Deputy Chairman of the Supervisory Board
Chairman of the Audit Committee
Member of the Nomination and Remuneration Committee
Colin Michael Bond who was born on January 26, 1960 in Upminster, United Kingdom, holds a Bachelor of Science degree in pharmacy and a master’s degree in business administration from London Business School. During his early career, Colin Michael Bond worked as auditor and management consultant for PricewaterhouseCoopers, Arthur Andersen and Procter & Gamble. From 2010 to 2016, he served as Chief Financial Officer (CFO) of Evotec SE, which is listed on the Frankfurt Stock Exchange (Prime Standard) as well as NASDAQ. From 2016 to 2022, Colin Michael Bond served as Chief Financial Officer (CFO) of Vifor Pharma Management AG. From 2022 to June 2024, he served as Chief Financial Officer (CFO) of Sandoz AG. Colin Michael Bond is a Fellow of the Institute of Chartered Accountants in England and Wales, and a member of the Royal Pharmaceutical Society of Great Britain.
Alongside his office as a member of the Supervisory Board, Colin Michael Bond is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships:
Currently:
- BioPharma Credit Plc, Leeds, United Kingdom, member of the board of directors.
- Agomab Therapeutics NV, Antwerp, Belgium, member of the board of directors
- Oxford Biomedica PLC, Oxford, United Kingdom, member of the board of directors (as of January 1, 2025)
Previously:
- Sandoz AG, Basel, Switzerland, member of the board of directors (from 2022 to 2024);
- Siegfried Holding AG, Zofingen, Switzerland, member of the board of directors (from 2013 to 2023); and
- Vifor Pharma Management AG, Glattbrugg, Switzerland, member of the board of directors (from 2016 to 2022).
Other than listed above, Colin Michael Bond is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership.
Nicholas Haggar
Member of the Supervisory Board
Member of the Audit Committee
Chairman of the Nomination and Remuneration Committee
Nicholas Haggar who was born on April 25, 1965 in Norwich, United Kingdom, has over thirty years of experience in building pharmaceutical businesses. With an Master of Business Administration from Cranfield School of Management and a Bachelors Degree in Industrial and Manufacturing Systems Engineering, Nicholas Haggar began his professional career in pharmaceutical technical operations before moving into commercial and enterprise leadership. Nicholas serves on the Zentiva board since 2023, having been Chief Executive Officer of Zentiva following its carve-out from Sanofi in 2018. Nicholas Haggar has been active in the biosimilar space for the last 15 years. Currently, he serves as Chief Executive of HealthQube Ltd., a UK-based investment, analytics and consultancy platform.
Alongside his office as a member of the Supervisory Board, Nicholas Haggar is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:
Currently:
- Zentiva K.S. International, Prague, Czech Republic, non-executive director;
- Biocon Limited, Bangalore, India, independent director;
- Biocon Biologics Ltd., Bangalore, India, independent director;
- Biocon Biologics UK Ltd., London, United Kingdom, non-executive director;
- Biosimilars NewCo Ltd., London, United Kingdom, non-executive director;
- Biosimilars Collaborations Ireland Ltd., Dublin, Ireland, non-executive director;
- Healthqube Ltd, Chalfont St. Giles, United Kingdom, chief executive officer; and
- Polpharma Generic BV, non-executive chairman.
Previously:
- Zentiva K.S., Prague, Czech Republic, chief executive officer (from 2019 to 2023).
Other than listed above, Nicholas Haggar is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.
Klaus Röhrig
Member of the Supervisory Board
Klaus Röhrig, who was born on July 21, 1977 in Vienna, Austria, studied business administration at the Vienna University of Economics and Business. He holds a Master of Economics and Business Administration from Vienna University of Economics and Business Administration. In 2000, he started his career at Credit Suisse First Boston in London, United Kingdom, focusing on corporate finance and M&A for technology companies. From 2002 to 2006, he worked for Mercury Capital GmbH in Vienna, Austria. In 2006, he joined Elliott Associates in London, United Kingdom, where he worked until 2012 and was responsible for the funds’ investments in the German speaking countries. Since 2015, he is founding partner and Co-Chief Investment Officer of Active Ownership Capital S.à r.l., an independent, partner-managed investment firm operating primarily in Continental Europe and Scandinavia.
Alongside his office as a member of the Supervisory Board, Klaus Röhrig is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:
Currently:
- Agfa-Gevaert N.V., Belgium, member of board of directors (non-executive director);
- Fagron NV, Belgium, member of board of directors (non-executive director);
- Francotyp-Postalia Holding AG, deputy chairman of the supervisory board;
- R3 Capital GmbH, Vienna, Austria, managing director;
- R3ND Immobilien GmbH, Vienna, Austria, managing director;
- Mercury Capital GmbH, Vienna, Austria, managing director;
- MAM Baby AG, Wollerau, Switzerland, member of the board of directors;
- Active Ownership Corporation S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- Active Ownership Capital S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- White Elephant Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- White Elephant S.à. r.l., Grevenmacher, Luxembourg,, member of the management board;
- AOC Technology SAS, Grevenmacher, Luxembourg, member of the management board;
- AOC Value SAS, Grevenmacher, Luxembourg, member of the management board;
- H2APEX Management S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- AOC Health Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- AO Gaming S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- AOC Cloud S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- Aonic Holdco S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- Aonic Holdco 2 S.à. r.l., Grevenmacher, Luxembourg, member of the management board;
- Aonic Midco S.à. r.l., Grevenmacher, Luxembourg, member of the management board
- AO MLP S.à. r.l., Grevenmacher, Luxembourg, member of the management board; and
- AOC Pharma S.à. r.l., Grevenmacher, Luxembourg, member of the management board.
Previously: none
Other than listed above, Klaus Röhrig is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.
Dr. Bodo Coldewey
Member of the Supervisory Board
Dr. Bodo Coldewey, who was born on December 16, 1971 in Oldenburg, Germany, completed his studies in business engineering at the Technical University of Kaiserslautern and his doctorate at the Leipzig Graduate School of Management. In 1997, he began his professional career as consultant at KPMG Deutschland, where he worked until June 2000. In July 2000, he joined 3i Group plc as investment manager, where he worked until September 2002. From October 2002 to December 2011, Dr. Bodo Coldewey served as director of Oldenburgische Landesbank AG. Since 2012, he is managing director of the family office WEGA Invest GmbH.
Alongside his office as a member of the Supervisory Board, Dr. Bodo Coldewey is, or was within the last five years, a member of the administrative, management or supervisory bodies of and/or a partner in the following companies and partnerships outside Formycon:
Currently:
- WEGA Support GmbH, managing director;
- WEGA Invest GmbH, managing director;
- WEGA Beteiligungsverwaltungsgesellschaft mbH, managing director;
- Dozena GmbH, managing director;
- PW Garrel Verwaltungs GmbH, managing director;
- BW Garrel Verwaltungs GmbH, managing director; and
- WEGA EQUITY AUDA Beteiligungs-GmbH i.L., managing director and liquidator.
Previously: None
Other than listed above, Dr. Bodo Coldewey is not, and was not within the last five years, a member of any administrative, management or supervisory body of and/or a partner in any other company or partnership outside Formycon.
Financial Calendar
Financial Calendar
Publications,
Webcasts and Events
Formycon believes in open dialogue with its investors and with the capital markets, as an integral part of its corporate philosophy. In addition to the publication dates for our financial results and the Annual General Meeting, this section provides an overview of the investor conferences that representatives of the Management Board will be attending in the coming weeks.
2025
Ad-Hoc Releases
Ad-Hoc Releases
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
